Peñalver-Piñol, Arnau
Benavente, Yolanda
Frias-Gomez, Jon
Alguacil, Juan
Santibañez, Miguel
Contreras-Llanes, Manuel
Peremiquel-Trillas, Paula
López-Querol, Marta
Paytubi, Sonia
Pelegrina, Beatriz
Onieva, Irene
Martínez, José Manuel
Fernandez-Gonzalez, Sergi
Francisco, Javier de
Caño, Víctor
Brunet, Joan
Pineda, Marta
Ponce, Jordi
Matias-Guiu, Xavier
Bosch, Francesc Xavier
Sanjosé, Silvia de
Alemany, Laia
Costas, Laura
Funding for this research was provided by:
CIBER-ESP (CB06/02/0073)
Generalitat de Catalunya (2021SGR01354 and 2021SGR1112)
Instituto de Salud Carlos III (projects PIE16/00049, PI19/01835, CM19/00216 and FI20/00031)
Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00231, CB16/12/00234)
Fundación Científica Asociación Española Contra el Cáncer (GCTRA18014MATI)
Article History
Received: 20 July 2023
Accepted: 20 October 2023
First Online: 2 November 2023
Declarations
:
: The Screenwide study followed the national and international directives on ethics and data protection (Declaration of Helsinki and subsequent amendments; EU Regla-ment 2016/679) and the Spanish laws on data protection (Organic Law 3/2018; Law 14/2007 biomedical research). Study protocol was approved by the Ethics Committee for Clinical Research from the Bellvitge University Hospital (PR348/19).
: Participation in the study was voluntary, and all eligible subjects signed an informed consent form after receiving information about the study, before participating in any intervention.
: L.C. received supplies from Integrated DNA Technologies (IDT) and Roche Diagnostics at a 50% discount for the pilot study of this project and received a speaker’s honoraria from Roche. Idibell and Roche signed a contract to collaborate in the development of the bioinformatics pipeline. L.C. has received a competitive grant from Novosanis/European Association for Cancer Research (EARC) and received Colli-Pee® devices (Novosanis) for a research project free of charge. JHcispoly and IDIBELL signed a service agreement for another project on endometrial cancer.